A master protocol to investigate a novel therapy acetyl-l-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia

A master protocol to investigate a novel therapy acetyl-l-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia

Abstract Background The lack of approved treatments for the majority of rare diseases is reflective of the unique challenges of orphan drug development. Novel methodologies, including new functionally relevant endpoints, are needed to render the development process more feasible and appropriate for...

Full description

Bibliographic Details
Main Authors: T. Fields, M. Patterson, T. Bremova-Ertl, G. Belcher, I. Billington, G. C. Churchill, W. Davis, W. Evans, S. Flint, A. Galione, U. Granzer, J. Greenfield, R. Karl, R. Kay, D. Lewi, T. Mathieson, T. Meyer, D. Pangonis, F. M. Platt, L. Tsang, C. Verburg, M. Factor, M. Strupp
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Trials
Subjects:
Niemann-Pick disease type C (NPC)
GM2 gangliosidosis
Tay-Sachs disease (TSD)
Sandhoff disease
Ataxia telangiectasia
N-acetyl-l-leucine
Online Access:https://doi.org/10.1186/s13063-020-05009-3

Internet

https://doi.org/10.1186/s13063-020-05009-3

Similar Items